Open AccessP692: IMMUNE FACTORS MAINTAINING TREATMENT‐FREE REMISSION IN PATIENTS WITH CHRONIC MYELOID LEUKEMIA AFTER DISCONTINUATION OF IMATINIB
Author(s) -
Kwaśnik P.,
Zaleska J.,
LinkLenczowska D.,
Zawada M.,
Ochrem B.,
Bober G.,
Wasilewska E.,
Mędraś E.,
Hus I.,
Szarejko M.,
Prejzner W.,
GrzybowskaIzydorczyk O.,
KlonowskaSzymczyk A.,
Sacha T.,
Giannopoulos K.
Publication year - 2022
Publication title -
hemasphere
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.677
H-Index - 11
ISSN - 2572-9241
DOI - 10.1097/01.hs9.0000845652.56752.23
Subject(s) - discontinuation , imatinib , medicine , immune system , myeloid leukemia , peripheral blood mononuclear cell , immunology , imatinib mesylate , gastroenterology , real time polymerase chain reaction , minimal residual disease , oncology , leukemia , biology , gene , in vitro , biochemistry
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom